Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

50
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
50
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
34
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

240
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
240
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

64
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
64
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

621
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
621
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

36
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
36

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic profiling of metabolizing enzymes and transporters in 2 layers of Caucasian human skin.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Relating plaque psoriasis barrier function changes with the underlying skin morphology and physiology.

Journal of pharmaceutical sciences·2026
Same author

Virtual Bioequivalence Assessment of Long-Acting Injectable Suspensions Using PBPK Modeling: Part 2. Type I Error and Safe Space Analyses.

The AAPS journal·2026
Same author

Virtual Bioequivalence Assessment of Long-acting Injectable Suspensions Using PBPK Modeling: Part 1. Impact of particle Size on Formulation Variability.

The AAPS journal·2026
Same author

Mechanism-Based Predictions of Local Tissue and Systemic Exposure for Drug Products Delivered Through the Female Reproductive Tract.

Journal of clinical pharmacology·2026
Same author

Mechanistic Modelling of Lidocaine and Prilocaine Absorption from EMLA Cream upon Topical Application using Physiologically Based Pharmacokinetic Modelling.

AAPS PharmSciTech·2025

Related Experiment Video

Updated: Jun 15, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.6K

PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric Populations.

Fang Wu1, Eleftheria Tsakalozou1, Gilbert J Burckart2

  • 1Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.

Pharmaceutical Research
|March 27, 2025
PubMed
Summary

Physiologically based pharmacokinetic (PBPK) modeling can support bioavailability and bioequivalence assessments in pediatric populations by integrating drug and patient-specific data. Further research is needed to address data gaps for robust regulatory applications.

Keywords:
AbsorptionPBPK modelingPediatricsVirtual bioequivalence

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.6K

Related Experiment Videos

Last Updated: Jun 15, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.6K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.6K

Area of Science:

  • Pharmacokinetics
  • Drug Development
  • Pediatric Pharmacology

Background:

  • Physiologically based pharmacokinetic (PBPK) modeling is increasingly utilized in drug development.
  • Regulatory assessment of bioavailability (BA) and bioequivalence (BE) often relies on adult data.
  • Pediatric populations present unique physiological and developmental considerations for drug disposition.

Purpose of the Study:

  • To summarize the application and considerations of PBPK modeling for BA/BE assessment in pediatrics.
  • To highlight the potential of PBPK to bridge data gaps in pediatric drug development.
  • To discuss the regulatory utility of PBPK modeling in pediatric drug product development.

Main Methods:

  • Review of proceedings from a workshop on PBPK modeling in regulatory science.
  • Discussion of PBPK absorption modeling incorporating drug substance, formulation, and pediatric physiology.
  • Integration of diverse data into mechanistic PBPK models for decision-making.

Main Results:

  • PBPK modeling can support relative BA and BE assessments in pediatric populations.
  • PBPK models can predict formulation differences in pediatric drug absorption.
  • The totality of evidence integrated into PBPK models is crucial for decision-making.

Conclusions:

  • PBPK modeling offers a valuable tool for assessing pediatric BA/BE, especially when adult data is primary.
  • Incorporating pediatric-specific physiological and drug characteristics into PBPK models is essential.
  • Global research collaborations are necessary to fill critical data gaps for enhanced PBPK application in pediatrics.